Multidrug-Resistant Organisms
Learn about Multidrug-Resistant Organisms diagnosis, including clinical documentation requirements, medical coding guidelines, and healthcare best practices. Find information on MDRO treatment, infection prevention, and antibiotic resistance. This resource covers key aspects of Multidrug-resistant organism identification, laboratory testing, and reporting for clinicians, healthcare professionals, and medical coders. Explore relevant ICD-10 codes, antimicrobial susceptibility testing AST, and strategies for managing MDRO infections in healthcare settings.
Bacteria resistant to multiple antibiotics, making infections harder to treat.
Vary depending on the infection site, but can include fever, inflammation, and slow healing.
Hospitals, nursing homes, and other healthcare facilities.
ICD-10 Code Families
Complete code families applicable to Z16.35
When to use each related code
| Description | When to use |
|---|---|
| Multidrug-resistant infection | Infection resistant to multiple antibiotic classes. Specify organism and resistance profile. |
| Methicillin-resistant Staphylococcus aureus (MRSA) | Staphylococcus aureus infection resistant to methicillin. Code S. aureus infection with documented methicillin resistance. |
| Vancomycin-resistant Enterococcus (VRE) | Enterococcus infection resistant to vancomycin. Code enterococcal infection with documented vancomycin resistance. |
Best-practice checklist
- ✓MDRO diagnosis: Isolate identification
- ✓MDRO diagnosis: Antimicrobial susceptibility testing results
- ✓MDRO diagnosis: Specific organism documented (e.g., MRSA, CRE)
- ✓MDRO diagnosis: Infection site specified
- ✓MDRO diagnosis: Date of positive culture
Common pitfalls to avoid
Insufficient documentation specifying organism and resistance profile, leading to coding errors and lost revenue.
Variations in MDRO testing methods across facilities can hinder accurate identification and coding of resistant organisms.
Using non-specific codes for MDROs instead of precise resistance mechanism codes impacting reimbursement and surveillance data.
Best-practice tips
- 01Isolate patients with suspected MDROs promptly.
- 02Ensure proper specimen collection for accurate MDRO testing.
- 03Implement antibiotic stewardship programs to curb resistance.
- 04Document MDRO diagnosis, infection site, and treatment clearly.
- 05Educate staff on infection control and prevention measures for MDROs.
Step-by-step checklist
- 1
Verify positive culture & sensitivity test
- 2
Review prior antibiotic use (3 months)
- 3
Confirm organism matches MDR criteria
- 4
Check local antibiogram for guidance
- 5
Document infection site & severity
Ready-to-paste narrative
Patient presents with signs and symptoms suggestive of infection with multidrug-resistant organisms (MDRO). Clinical indications include (insert specific signs and symptoms e.g., fever, purulent drainage, productive cough, urinary frequency, dysuria). Patient history includes (mention relevant risk factors e.g., recent hospitalization, long-term care facility residence, prior antibiotic use, indwelling medical devices, immunocompromised status). Laboratory cultures were obtained from (specify source e.g., blood, urine, sputum, wound) and confirm the presence of (specify organism e.g., methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), carbapenem-resistant Enterobacteriaceae (CRE), extended-spectrum beta-lactamase (ESBL)-producing organisms). Antimicrobial susceptibility testing reveals resistance to multiple antibiotic classes (list specific antibiotics and results). Diagnosis of multidrug-resistant organism infection is confirmed. Treatment plan includes initiation of (specify antibiotic regimen based on susceptibility testing) and supportive care measures (e.g., fluid management, pain control, wound care). Infection control precautions (e.g., contact precautions, isolation) are implemented per institutional guidelines to prevent transmission. Patient education provided regarding infection prevention and control measures. Prognosis and potential complications discussed with the patient. Continued monitoring for treatment response and potential adverse effects will be conducted. ICD-10-CM code (specify appropriate code based on identified organism and site of infection) and appropriate CPT codes for microbiology and susceptibility testing will be utilized for billing and coding purposes. Differential diagnosis included (list alternative diagnoses considered). Plan for follow-up care outlined.
Common questions and answers
What are the most effective infection control strategies for preventing the spread of Multidrug-Resistant Organisms (MDROs) in hospital settings?+
Preventing the spread of MDROs like carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) requires a multifaceted approach. Key strategies include rigorous hand hygiene practices by all healthcare personnel, active surveillance cultures for high-risk patients, contact precautions and isolation for confirmed or suspected MDRO carriers, appropriate environmental cleaning and disinfection, and antimicrobial stewardship programs to optimize antibiotic use and minimize selective pressure for resistance. Furthermore, effective communication between healthcare facilities is crucial for tracking and managing MDRO transmission. Explore how implementing a comprehensive infection control bundle can improve patient outcomes and reduce MDRO prevalence in your institution.
How do I interpret Multidrug-Resistant Organism (MDRO) susceptibility testing results and choose the appropriate antibiotic therapy for complicated infections?+
Interpreting MDRO susceptibility testing results requires careful consideration of the organism identified, the antibiotics tested, and the minimum inhibitory concentration (MIC). For complicated infections involving MDROs such as extended-spectrum beta-lactamase (ESBL)-producing organisms or vancomycin-resistant Enterococci (VRE), consultation with an infectious diseases specialist is highly recommended. Treatment decisions should be based on the antibiogram, local resistance patterns, patient-specific factors (e.g., allergies, comorbidities, site of infection), and potential drug interactions. Consider implementing rapid diagnostic testing to facilitate timely and targeted antibiotic therapy, thereby improving patient outcomes. Learn more about the latest guidelines for MDRO treatment and management.
What are the emerging Multidrug-Resistant Organisms (MDROs) that pose the greatest threat to public health, and how can clinicians prepare for their potential impact?+
Several emerging MDROs, including colistin-resistant bacteria and carbapenemase-producing organisms, pose significant threats to public health due to limited treatment options. Clinicians should stay informed about these emerging threats through ongoing education and surveillance data from local public health agencies and the Centers for Disease Control and Prevention (CDC). Preparation involves strengthening infection control protocols, optimizing diagnostic capabilities for rapid identification, and promoting judicious antibiotic use. Consider implementing proactive strategies to address these emerging MDROs and mitigate their potential impact on patient care and public health. Explore how collaborative efforts between healthcare professionals, researchers, and public health agencies can help combat the rise of antimicrobial resistance.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.